Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Heparin-like glycosaminoglycan which is a mixture of low molecular weight heparin (80%) and dermatan sulfate (20%) that has hypolipaemic and antithrombotic properties and used for treatment of venous insufficiency.
It does not have significant effects on coagulation but some protective properties on vascular endothelium is attributed.
At latest update on excretion into breast milk no published data were found.
Pharmacokinetic data (large volume of distribution and high molecular weight) make it unlikely the passage into milk in significant amounts.
Until more published data about this drug regarding breastfeeding is available, a safer alternative should be used, especially during the neonatal period and in case of prematurity.